EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of local treatment on survival outcomes in patients with metastatic lung cancer with oligoprogression undergoing immunotherapy

Barbara Domenach, Valentine Mismetti iD, Wafa Bouleftour, Anne Bareille, Olivier Tiffet, Anne-Laure Desage, Pierre Fournel

Swiss Medical Weekly · 27.04.2026 · 156 (4) · 4790

DOI: 10.57187/4790 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Swiss Medical Weekly, online erschienen am 27.04.2026. Verfasst von Barbara Domenach und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology and Thoracic Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Immunotherapy, Immune Checkpoint Inhibitors. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Immune checkpoint inhibitors have revolutionised the management of non-small cell lung cancer (NSCLC) without oncogenic addictions and have improved its prognosis. A manifestation of acquired resistance to immunotherapy, which is typically seen in a restricted number of lesions and metastatic locations (oligoprogression), has been reported. In cases of oligoprogressive disease, local ablative therapies may represent the main therapeutic approaches, and their significance is further amplified for patients with metastatic NSCLC undergoing immunotherapy. METHODS: This monocentric retrospective study included 49 patients with metastatic NSCLC treated with immunotherapy, either as a standalone treatment or in combination with chemotherapy. The patients also underwent local ablative therapy in the context of oligoprogression. Clinical and oncological characteristics were assessed, along with overall survival and progression-free survival. RESULTS: The clinical and oncological characteristics were generally consistent with those expected in the general population of patients with metastatic NSCLC. A median overall survival of 28 months (95% CI: 17.4%–33%), measured from the initiation of local treatment, was reported. The 5-year overall survival rate was 12.36%, and the median progression-free survival was 7.56 months (95% CI: 6.01%–11%). The addition of local ablative therapy to immunotherapy was not associated with increased toxicity. CONCLUSION: The addition of local ablative therapy in cases of oligoprogression as part of the treatment of metastatic NSCLC treated with immunotherapy alone or in combination with chemotherapy appears to be a therapeutic strategy for slowing disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungImmunotherapyImmune Checkpoint InhibitorsHumansFemaleRetrospective StudiesMaleAgedMiddle AgedDisease ProgressionProgression-Free SurvivalNeoplasm MetastasisSurvival RateAged, 80 and overAdult

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pulmonology and Thoracic Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France.
  • SAINBIOSE (SAnté INgénierie BIOlogie St-Etienne) INSERM U1059, Jean Monnet University, Saint-Etienne, France.
  • Department of Medical Oncology, Saint-Etienne University Hospital-Etienne, Saint-Etienne, France.
  • Department of Radiotherapy, Saint-Etienne University Hospital-Etienne, Saint-Etienne, France.
  • Department of Thoracic Surgery, University Hospital of Saint Etienne, Saint Etienne, France.

ORCID-Profile: Valentine Mismetti

Zitieren

APA

Domenach, B., Mismetti, V., Bouleftour, W., Bareille, A., Tiffet, O., Desage, A. L., & Fournel, P. (2026). Impact of local treatment on survival outcomes in patients with metastatic lung cancer with oligoprogression undergoing immunotherapy. Swiss Medical Weekly, 156(4), 4790. https://doi.org/10.57187/4790

Vancouver

Domenach B, Mismetti V, Bouleftour W, Bareille A, Tiffet O, Desage AL, et al. Impact of local treatment on survival outcomes in patients with metastatic lung cancer with oligoprogression undergoing immunotherapy. Swiss Medical Weekly. 2026;156(4):4790. doi:10.57187/4790

BibTeX
@article{Domenach2026,
  author = {Domenach, Barbara and Mismetti, Valentine and Bouleftour, Wafa and Bareille, Anne and Tiffet, Olivier and Desage, Anne-Laure and Fournel, Pierre},
  title = {Impact of local treatment on survival outcomes in patients with metastatic lung cancer with oligoprogression undergoing immunotherapy},
  journal = {Swiss Medical Weekly},
  year = {2026},
  volume = {156},
  number = {4},
  pages = {4790},
  doi = {10.57187/4790}
}
Kostenlos starten →